Thrombolytic therapy is currently the main strategy for the treatment of ischemic stroke; recombinant tissue plasminogen activator (r-tPA) is the only FDA-approved drug for IS treatment in the United States, but due to its narrow treatment time window (<4.5 h) and side effects such as hemorrhagic transformation, only few patients can benefit from it (Powers et al., 2019). The gene discussed is PLAT; the disease is ischemic stroke.